Key insights
- A Los Angeles jury awarded $32 million to a family in an asbestos-related talc case against Johnson & Johnson. The jury found J&J liable for a woman's death from mesothelioma, attributing it to exposure from the company's baby powder. This verdict highlights ongoing legal risks for J&J, potentially impacting investor sentiment and future financial liabilities, though the direct market impact on the large-cap stock may be limited given its diversified business.
LOS ANGELES - A Los Angeles jury awarded $32 million to the family of Maria Lozano, a California woman who died from pleural mesothelioma in 2024, finding Johnson & Johnson (NYSE:JNJ) and its subsidiaries liable for her illness, according to a press release statement.
The verdict was reached after the jury concluded that Lozano’s mesothelioma resulted from decades of exposure to asbestos-contaminated talc in Johnson & Johnson’s baby powder. Lozano used the talc-based product on herself and her children from the early 1970s until her death.
Her children, John Lozano, Araceli Lenard-Lozano and Jeanette Lozano, continued the lawsuit after their mother’s death.
During the trial, Johnson & Johnson argued that Lozano’s asbestos exposure stemmed from environmental conditions in Mexico City, where she lived for the first 21 years of her life, as well as from cosmetic products and her husband’s automotive work. The jury rejected these alternate exposure theories and assigned 0% fault to the Mexico City facilities, cosmetic products and automotive products.
"The jury carefully considered the evidence and concluded that Maria Lozano’s mesothelioma was caused by decades of exposure to asbestos-contaminated Johnson’s Baby Powder," said Danny Kraft, an attorney with Dean Omar Branham Shirley who represented the family at trial.For investors monitoring JNJ’s legal exposure and financial health, InvestingPro offers a comprehensive Pro Research Report with expert analysis on the company’s risk factors and valuation.
The family’s legal team presented evidence during the trial showing that Johnson & Johnson failed to adequately warn consumers about dangers associated with asbestos-contaminated talc despite longstanding knowledge of the risks.
The case is Lozano v. Johnson & Johnson, Coordinated Proceeding Special Title LAOSD Asbestos Cases, Coordinated Case No. JCCP 4674, in the Superior Court of California for the County of Los Angeles.
In other recent news, Johnson & Johnson announced it will acquire Firefly Bio for $1 billion in cash, marking a significant move in the biotechnology sector. The acquisition aims to enhance Johnson & Johnson’s capabilities in targeting KRAS-driven tumors through Firefly Bio’s degrader antibody conjugate platform, Firelink. Additionally, the company reported positive results from its Phase 2 JASMINE study, where nipocalimab showed a significant decrease in disease activity for patients with moderate-to-severe systemic lupus erythematosus. In its oncology segment, Johnson & Johnson revealed that its Phase 3 PROTEUS study demonstrated apalutamide, combined with hormone therapy, reduced the risk of metastasis or death by 20% in prostate cancer patients. The company’s medical device subsidiary, Abiomed, successfully defended against patent infringement allegations concerning its Impella heart pumps. Furthermore, the FDA approved an expanded label for Tremfya, supporting its role in inhibiting the progression of joint damage in psoriatic arthritis patients. These developments highlight Johnson & Johnson’s ongoing advancements in pharmaceuticals and medical devices.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for JNJ plus thousands of other stocks and find your next hidden gem with massive upside.